← All trials
NCT04856150
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Jan 31, 2023
- First posted
- Apr 23, 2021
- Last posted
- Apr 23, 2021
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qure Healthcare, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.